Literature DB >> 15381333

Peptide and peptide analog transport systems at the blood-CSF barrier.

David E Smith1, Conrad E Johanson, Richard F Keep.   

Abstract

In addition to being the main source of cerebrospinal fluid (CSF) secretion, the choroid plexuses are involved in the supply and distribution of peptides to brain, the removal of toxic metabolites, the excretion of xenobiotics, and the delivery of drugs as an alternative route to the blood-brain barrier (BBB). The discovery of proton-coupled oligopeptide transporters in choroid plexus has generated considerable interest regarding their physiologic role at the blood-cerebrospinal fluid interface and their potential for peptide/antagonist pharmacotherapy in the central nervous system. Many of the same factors that affect the disposition of naturally occurring peptides in brain will also affect the disposition of exogenously delivered peptide or peptidomimetic drugs. Therefore, this review addresses three main areas: (1) choroid plexus structure, physiology, and barrier function in relation to peptide transport; (2) polypeptide transport and secretion mechanisms into cerebrospinal fluid; and (3) molecular physiology, expression, and functional activity of proton-coupled oligopeptide transporters in choroid plexus.

Mesh:

Substances:

Year:  2004        PMID: 15381333     DOI: 10.1016/j.addr.2004.07.008

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  50 in total

1.  Kyotorphin transport and metabolism in rat and mouse neonatal astrocytes.

Authors:  Jianming Xiang; Huidi Jiang; Yongjun Hu; David E Smith; Richard F Keep
Journal:  Brain Res       Date:  2010-06-09       Impact factor: 3.252

2.  ABC and SLC transporter expression and proton oligopeptide transporter (POT) mediated permeation across the human blood--brain barrier cell line, hCMEC/D3 [corrected].

Authors:  Stephen M Carl; David J Lindley; Debanjan Das; Pierre O Couraud; Babette B Weksler; Ignacio Romero; Stephanie A Mowery; Gregory T Knipp
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

Review 3.  Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route.

Authors:  Conrad E Johanson; John A Duncan; Edward G Stopa; Andrew Baird
Journal:  Pharm Res       Date:  2005-07-22       Impact factor: 4.200

4.  Vascular Pathology as a Potential Therapeutic Target in SCI.

Authors:  Richard L Benton; Theo Hagg
Journal:  Transl Stroke Res       Date:  2011-11-29       Impact factor: 6.829

Review 5.  Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?

Authors:  Lucy Sanchez-Covarrubias; Lauren M Slosky; Brandon J Thompson; Thomas P Davis; Patrick T Ronaldson
Journal:  Curr Pharm Des       Date:  2014       Impact factor: 3.116

Review 6.  Vectorial ligand transport through mammalian choroid plexus.

Authors:  Reynold Spector; Conrad E Johanson
Journal:  Pharm Res       Date:  2010-05-15       Impact factor: 4.200

7.  Influence of peptide transporter 2 (PEPT2) on the distribution of cefadroxil in mouse brain: A microdialysis study.

Authors:  Xiaomei Chen; Richard F Keep; Yan Liang; Hao-Jie Zhu; Margareta Hammarlund-Udenaes; Yongjun Hu; David E Smith
Journal:  Biochem Pharmacol       Date:  2017-02-10       Impact factor: 5.858

8.  Expression profiling of the solute carrier gene family in the mouse brain.

Authors:  Amber Dahlin; Josh Royall; John G Hohmann; Joanne Wang
Journal:  J Pharmacol Exp Ther       Date:  2009-01-29       Impact factor: 4.030

9.  Glycyl-L-glutamine disposition in rat choroid plexus epithelial cells in primary culture: role of PEPT2.

Authors:  Yongjun Hu; Scott M Ocheltree; Jianming Xiang; Richard F Keep; David E Smith
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

10.  Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene.

Authors:  Haichuan Duan; Joanne Wang
Journal:  J Biol Chem       Date:  2012-12-19       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.